IMI Issues Statement Concerning Patents

IMI Issues Statement Concerning Patents 


TORONTO, Aug. 3  /PRNewswire-FirstCall/ -- IMI International Medical
Innovations Inc. (TSX: IMI; Amex: IME) today announced that it has learned that
two of its U.S. skin cholesterol patents have been listed as abandoned by the
United States Patent and Trademark Office (PTO) for failure to pay maintenance
fees. IMI noted that the failure to pay these maintenance fees appears to have
occurred while the files were being transferred between U.S. and Canadian
patent agents. IMI and its agents have initiated the process to seek
reinstatement of the patents.

IMI has additional U.S. patents and patent applications that relate to its skin
cholesterol products that are in good standing. IMI's patents in Europe, Canada
and other territories have not been affected. The process of reinstating the
affected U.S. patents could take several months, and there is no assurance that
they will be successful in having the patents reinstated. IMI believes that
this situation will not affect the commercialization plans for the skin
cholesterol products.

About IMI

IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases. IMI's
cardiovascular products are branded as PREVU(x) Coronary Heart Disease
Predictor. The company's cancer tests include ColorectAlert(TM), LungAlert(TM)
and a breast cancer test. IMI's head office is located in Toronto, and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For further information, please visit
http://www.imimedical.com/.

This release contains forward-looking statements that reflect the company's
current expectations regarding future events. The forward-looking statements
involve risks and uncertainties. Actual events could differ materially from
those projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely completion of
clinical studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to time
in the company's quarterly, annual and other regulatory filings. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Ron Hosking, Vice President Finance & CFO, T: [phone],

; Dr. Brent Norton, President and CEO, T:

[phone], 

Copyright